Forma Therapeutics Appoints Biopharma Veteran Thomas G. Wiggans to Board of Directors
09 September 2020 - 9:05PM
Business Wire
Forma Therapeutics Holdings, Inc. (Nasdaq: FMTX), a
clinical-stage biopharmaceutical company focused on rare
hematologic diseases and cancers, today announced the appointment
of industry veteran Thomas G. Wiggans to its board of directors.
Mr. Wiggans has led successful biopharmaceutical companies from
start-up stage into the clinic and later global commercialization,
served on the boards of numerous public and private companies, and
was instrumental in the formation of the Biotechnology Industry
Organization, now Biotechnology Innovation Organization (BIO).
“I am delighted to welcome Tom to our board,” said Peter Wirth,
chair of Forma’s board of directors. “Tom’s distinguished career as
a leader of biopharma companies, as well as an entrepreneur, will
serve as a critical resource to Forma.”
“Tom brings decades of experience leading the development and
commercialization of new therapeutics,” said Frank Lee, president
and chief executive officer of Forma. “We look forward to
leveraging his expertise to execute on our corporate and clinical
strategies on behalf of the sickle cell community and those
affected by prostate cancer.”
“I am excited to join Forma’s board at such a pivotal moment in
the company’s growth,” said Wiggans. “I look forward to working
with the executive team and other accomplished board members to
contribute to the company’s mission of bringing transformative
medicines to patients with rare hematologic diseases and
cancers.”
About Mr. Wiggans
Mr. Wiggans is a veteran biopharmaceutical executive, having
founded Dermira (NASDAQ: DERM) in 2010 and served as its chairman
and chief executive officer until it was acquired by Eli Lilly and
Company in February 2020. Prior to founding Dermira, Mr. Wiggans
served as chairman and chief executive officer of Peplin, Inc.
until Peplin’s acquisition by LEO Pharma A/S in 2009. He also
served as chairman of the board of directors and chief executive
officer of Connetics Corporation until it was acquired by Stiefel
Laboratories, Inc. in 2006. Prior to Connetics, he served as
president and chief operating officer of CytoTherapeutics Inc. and
in various management positions at Ares-Serono S.A., including as
president of its U.S. pharmaceutical operations and managing
director of its U.K. pharmaceutical operations. He began his career
with Eli Lilly and Company.
Mr. Wiggans has served on the boards of numerous public and
private companies including Excaliard, Somaxon, Corthera, Sangamo
and Onyx. He is a long-standing member of the board of directors of
BIO, as well as a member of the board of trustees of the University
of Kansas Endowment Association. He holds a B.S. in pharmacy from
the University of Kansas and an M.B.A. from Southern Methodist
University.
About Forma Therapeutics
Forma Therapeutics is a clinical-stage biopharmaceutical company
focused on the research, development and commercialization of novel
therapeutics to transform the lives of patients with rare
hematologic diseases and cancers. Our R&D engine combines deep
biology insight, chemistry expertise and clinical development
capabilities to create drug candidates with differentiated
mechanisms of action focused on indications with high unmet need.
Our work has generated a broad proprietary portfolio of programs
with the potential to provide profound patient benefit. For more
information, please visit www.FormaTherapeutics.com or follow us on
Twitter @FORMAInc and LinkedIn.
Forward-looking Statements
This press release contains forward-looking statements within
the meaning of the Private Securities Litigation Reform Act of
1995, as amended, including, without limitation, express or implied
statements regarding the advancement of our clinical programs, our
expectations of the therapeutic benefits related thereto, the
timing and success of ongoing clinical trials, and our growth as a
company and the anticipated contribution of the members of our
board of directors to our operations and progress. The words “may,”
“will,” “could,” “would,” “should,” “expect,” “plan,” “anticipate,”
“intend,” “believe,” “estimate,” “predict,” “project,” “potential,”
“continue,” “target” and similar expressions are intended to
identify forward-looking statements, although not all
forward-looking statements contain these identifying words.
Any forward-looking statements in this press release are based
on management’s current expectations and beliefs and are subject to
a number of risks, uncertainties and important factors that may
cause actual events or results to differ materially from those
expressed or implied by any forward-looking statements contained in
this press release, including, without limitation, those risks and
uncertainties related to the advancement of our clinical program,
the expected impact and contribution of our board of directors and
executives to our business, and other risks identified in our SEC
filings, including those risks discussed under the heading “Risk
Factors” in our Quarterly Report on Form 10-Q for the quarter ended
June 30, 2020, as well as other risks detailed in our subsequent
filings with the SEC. We caution you not to place undue reliance on
any forward-looking statements, which speak only as of the date
they are made. We disclaim any obligation to publicly update or
revise any such statements to reflect any change in expectations or
in events, conditions or circumstances on which any such statements
may be based, or that may affect the likelihood that actual results
will differ from those set forth in the forward-looking statements.
Any forward-looking statements contained in this press release
represent our views only as of the date hereof and should not be
relied upon as representing its views as of any subsequent date. We
explicitly disclaim any obligation to update any forward-looking
statements.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20200909005195/en/
Media Contact: Kari Watson, +1 781-235-3060 MacDougall
kwatson@macbiocom.com
Investor Contact: Stephanie Ascher, +1 212-362-1200 Stern
Investor Relations stephanie.ascher@sternir.com
Forma Therapeutics (NASDAQ:FMTX)
Historical Stock Chart
From Jul 2024 to Aug 2024
Forma Therapeutics (NASDAQ:FMTX)
Historical Stock Chart
From Aug 2023 to Aug 2024